Barclays
GRI

Barclays’s GRI Bio GRI Stock Holding History

Barclays’s Portfolio GRI Stock Details GRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147 Buy
+83
New +$184 ﹤0.01% 5150

Other funds holding GRI

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Barclays's GRI Position: Q2 2026 in Review

Barclays opened a new position in GRI Bio (GRI) in Q2 2026: 83 shares worth $147. The stake represents ﹤0.01% of the portfolio and ranks #5150 among its holdings.

11 funds tracked by Wall St. Rank hold GRI as of Q2 2026.

  • Barclays held 83 shares of GRI Bio worth $147 as of Q2 2026.
  • GRI Bio was a new Barclays position in Q2 2026.
  • GRI Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5150 holding.
  • 11 funds tracked by Wall St. Rank held GRI Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.